Forward-Looking Statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of Haemonetics Corporation (the “Company”), including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the impact of the COVID-19 pandemic on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences.

Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the impact of the COVID-19 pandemic, including the scope and duration of the outbreak; government actions and restrictive measures implemented in response; availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from the Company’s acquisition of Cardiva Medical Inc., including any failure to realize the anticipated benefits of the transaction; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
Management’s use of Non-GAAP Financial Measures

This presentation contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. In this presentation, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this presentation, organic revenue growth excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. Adjusted operating income and adjusted earnings per diluted share exclude restructuring and restructuring related costs, deal amortization expenses, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, integration and transaction costs, gains and losses on dispositions, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted earnings per diluted share also excludes the tax impact of these items. Free cash flow before restructuring and restructuring related costs is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included on the Company’s website at www.haemonetics.com.
Haemonetics At-A-Glance

Global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.
Long-term value creation strategy that is supported by multiple value drivers

Corporate Strategy

Compete in winning segments and geographies

Achieve leading position in each segment where we compete

Deliver superior short-term and long-term operating performance (ROIC)

Value drivers

1. Plasma market
2. Hospital market
3. Mergers & Acquisitions
4. Innovation Agenda
5. Operational Excellence
6. Resource Allocation
FY21 revenue snapshot in the customer-centric business unit structure

<table>
<thead>
<tr>
<th></th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA$^1$</td>
<td>9%</td>
</tr>
<tr>
<td>% Disp. revenue$^2$</td>
<td>93%</td>
</tr>
<tr>
<td>% NA disp. revenue (excluding solutions)$^3$</td>
<td>80%</td>
</tr>
<tr>
<td><strong>Blood Center</strong></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA$^1$</td>
<td>72%</td>
</tr>
<tr>
<td>% Disp. revenue$^2$</td>
<td>94%</td>
</tr>
<tr>
<td><strong>Hospital</strong></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA$^1$</td>
<td>41%</td>
</tr>
<tr>
<td>% Disp. revenue$^2$</td>
<td>70%</td>
</tr>
<tr>
<td>% HM revenue$^4$</td>
<td>51%</td>
</tr>
<tr>
<td><strong>Service</strong></td>
<td></td>
</tr>
<tr>
<td>% Revenue ex. NA$^1$</td>
<td>52%</td>
</tr>
</tbody>
</table>

1. Revenue excluding North America
2. Disposables revenue
3. North America (NA) disposables revenue excluding liquid solutions
4. Hemostasis Management
5. Fiscal 2021 revenue percentages include one month of revenue for Cardiva Medical Inc. acquired on March 1, 2021. For more information please refer to the Company’s Q4 FY’21 earnings release and other filings with the SEC.
Leading position in Plasma with modern, fully integrated technology solutions

Plasmapheresis

- Capital/Disposables
  - NexSys PCS®/PCS®2

- Growth

Software

- Software Solutions
  - NexLynk DMS®

- Developing

Business Model

Product Portfolio

Market Lifecycle

Market Position

Competition

1. Device subject to 510(k) clearance

1. Fresenius Fenwal (Aurora), Terumo¹, Other (OUS)

1. MAK, homegrown

NexSys PCS®
Collection device

NexLynk DMS®
Donor management software

Donor 360™
Mobile app

¹. Fresenius Fenwal (Aurora), Terumo

© 2022 Haemonetics Corporation
Three Blood Center portfolios that offer safe, reliable blood collection solutions

- **Apheresis**
  - Capital/Disposables: MCS+ Suite, ACP-215
  - Mature: Fresenius, Terumo

- **Whole Blood**
  - Disposables: Manual Blood Collections and Filtration
  - Mature: Fresenius, Terumo, Macopharma
Robust growth in the plasma-derived therapeutics and customer capital investments support anticipated 8-10% average growth of the source plasma collections market.

Drivers of the robust growth in plasma-derived therapeutics

- Indications (>8,000 registered clinical trials)
- Formulations (eg. IV->SC)
- Diagnosis rates
- Population

Capital investments across customers

- +30% Increase in fractionation capacity (66M → 86M liters)
- ~11% Average growth in US source plasma collections
- ~12% Average growth in the number of US plasma centers

2. IV – Intravenous; SC – Subcutaneous.
5. For the period from calendar year 2015 through 2019.
NexSys platform improves customer identified tangible value drivers

**Plasma Yield**
- Increased Plasma yield by 18-26ml per donation on average through YES® Technology¹

**Quality and Compliance**
- >98% reduction in documentation errors²
- Bi-directional, paperless workflow helps eliminate errors and enforces compliance

**Productivity**
- 16 minute reduction in donor door-to-door time²
- Increased labor effectiveness
- Business Optimization support

**Donor Experience**
- Reduced donation times
- Increased donor engagement and satisfaction
- Improved staff responsiveness
- 93% donor preference for NexSys PCS³

---
¹ Plasma yield enhancing solution; YES® Technology is available in the United States only
² In-market results from NexSys PCS/NexLynk DMS implementations baselined versus Haemonetics PCS®2 device use, non bi-directionally integrated with Haemonetics DMS
³ When compared with the prior generation device based on in-market survey data
The Persona™ Plasma Collection Solution Enables the new Persona Nomogram

Persona™ a proprietary integrated plasma collection solution built upon the NexSys PCS® platform, is the first and only donor-tailored solution clinically shown to yield +9% to 12%¹ more plasma per donation on average to maximize both cost-efficient output and patient impact.

1. Based on baseline device, software configuration, and donor population
Blood Center market remains challenging. Significant cash flow opportunity

**Market:**
- Decline in blood transfusion rates due to:
  - Decline in invasive surgeries
  - Improvements in BMP\(^1\)
  - Pharmaceuticals
- High-yield, multi-dose collections are becoming a new standard
- Tender-driven business creates pricing pressures (mostly OUS)

**HAE Opportunity:**
- Complexity reduction through:
  - Standardized technology
  - Optimized product portfolio
  - Reduced commercial footprint
- Customized pricing strategies
- Strategic resource allocation
- Improvements in cost of goods sold
- Focus on profitability and cash flow

---
© 2022 Haemonetics Corporation
Leading positions within four synergistic Hospital markets with state-of-the-art product offering

**Business Model**
- **Hemostasis Management**: Capital/Disposables
- **Cell Salvage**: Capital/Disposables
- **Transfusion Management**: Software Solutions
- **Vascular Closure Devices**: Disposables

**Product Portfolio**
- **Hemostasis Management**
  - TEG® 5000, TEG®6s & TEG Manager, ClotPro
- **Cell Salvage**
  - Cell Saver® Elite® +
- **Transfusion Management**
  - SafeTrace Tx®/BloodTrack®
- **Vascular Closure Devices**
  - SafeTrace Tx®/Vascade®/Vascade MVP®

**Market Lifecycle**
- **Hemostasis Management**: Developing
- **Cell Salvage**: Mature
- **Transfusion Management**: Mature/Developing
- **Vascular Closure Devices**: Mature/Developing

**Competition**
- **Hemostasis Management**
  - IL (ROTEM), Stago (HemaSonics)
  - LivaNova, Fresenius, Medtronic
- **Cell Salvage**
  - Cell Saver®, Elite®+
- **Transfusion Management**
  - Cerner, Mediware / MSoft
- **Vascular Closure Devices**
  - Terumo, Abbott, Cardinal Health / Manual Compression

© 2022 Haemonetics Corporation
Strong market opportunity reinforces Hospital as a growth driver for Haemonetics

FY’22 Hospital Market Opportunity

- **Vascular Closure Devices**
  - Interventional Cardiology ($1.9B)
  - Electrophysiology ($0.9B)

- **Hemostasis Management**
  - Interventional Cardiology
  - CV Surgery
  - Trauma
  - Liver transplant
  - External labs

- **Transfusion Management**
  - Next generation BB
  - Smarter and safer BIMS

- **Cell Salvage**
  - CV Surgery
  - Orthopedics
  - Trauma

~$4.0B

$0.2B

$0.3B

$0.7B

$2.8B

1. Annual disposables market opportunity in core clinical segments.
2. HIMSS Logic Database.
4. Hemostasis Management products are not being used in external labs today representing a new market opportunity.
Our productivity programs reduce inefficiency and free up resources to fund growth investments

<table>
<thead>
<tr>
<th>Complexity Reduction Program&lt;sup&gt;3&lt;/sup&gt;</th>
<th>Operational Excellence Program&lt;sup&gt;4&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Timing</strong></td>
<td>FY20 – FY25</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>G&amp;A, productivity</td>
</tr>
<tr>
<td><strong>Gross Savings (target)</strong></td>
<td>$80M+</td>
</tr>
<tr>
<td><strong>Net Savings&lt;sup&gt;1&lt;/sup&gt; (target)</strong></td>
<td>Modest</td>
</tr>
<tr>
<td><strong>One-time program costs&lt;sup&gt;2&lt;/sup&gt;</strong></td>
<td>$50 - $60M</td>
</tr>
<tr>
<td><strong>Net Savings</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td>$115M - $125M</td>
</tr>
<tr>
<td><strong>One-time program costs</strong></td>
<td>$95M - $105M</td>
</tr>
</tbody>
</table>

1. The amount of savings estimated to drop through to the bottom line by the end of the program.
2. Include restructuring charges over the course of the program. These charges will be excluded from the adjusted results.
3. The Complexity Reduction Program has been substantially completed at the end of FY'20 having delivered gross savings of $80M+ and resulted in total cumulative one-time costs of $58.8M as of April 3, 2021.
4. The Operational Excellence Program is projected to deliver $67M in cumulative target gross savings by the end of FY’22. Cumulative one-time costs under this program were $47.2M as of January 1, 2022.
5. The Company will issue updated net savings guidance in FY'23.
Capital allocation priorities to support organic and inorganic value creation

1. Organic business needs (R&D, S&M, CAPEX)
2. Inorganic growth opportunities (including M&A)
3. Share repurchases
Superior results:
Sustaining revenue growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (US $ Millions)</th>
<th>Revenue growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY’16</td>
<td>$910</td>
<td>0%</td>
</tr>
<tr>
<td>FY’17</td>
<td>$886</td>
<td>-3%</td>
</tr>
<tr>
<td>FY’18</td>
<td>$904</td>
<td>2%</td>
</tr>
<tr>
<td>FY’19</td>
<td>$968</td>
<td>7%</td>
</tr>
<tr>
<td>FY’20</td>
<td>$988</td>
<td>2%</td>
</tr>
</tbody>
</table>

1. Adjusted for the 53rd week in FY’16. Please refer to the earnings release for FY’16 for more detail.
2. Organic revenue growth excludes the impact of currency, product line end-of-life decisions as well as acquisition and divestiture activities.
Superior results: Stronger Operating and Financial leverage

<table>
<thead>
<tr>
<th>Operating Margin¹</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY16</td>
<td>FY20</td>
<td></td>
</tr>
<tr>
<td>GAAP (5%)</td>
<td>10%</td>
<td></td>
</tr>
<tr>
<td>Adjusted²</td>
<td>13%</td>
<td>22%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Earnings Per Share</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY16</td>
<td>FY20</td>
<td></td>
</tr>
<tr>
<td>GAAP ($1.09)</td>
<td>$1.48</td>
<td></td>
</tr>
<tr>
<td>Adjusted²</td>
<td>$1.63</td>
<td>$3.31</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cash Flow</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY16</td>
<td>FY20</td>
<td></td>
</tr>
<tr>
<td>CFO</td>
<td>$122M</td>
<td>$158M</td>
</tr>
<tr>
<td>FCF²,³</td>
<td>$58M</td>
<td>$139M</td>
</tr>
</tbody>
</table>

1. Operating Margin percentage is calculated as Operating Income/Loss divided by Revenue (as Reported); Adjusted Operating Margin percentage is calculated as Adjusted Operating Income divided by Revenue, adjusted to exclude $1.9M in Plasma revenue due to an accelerated charge incurred as a result of the divestiture of the Union, South Carolina liquid solutions operation.
2. For more information, including a reconciliation of GAAP to non-GAAP adjusted results, please refer to the Company’s earnings releases for the applicable periods at http://haemonetics.gcs-web.com/.
3. Free cash flow before restructuring & turnaround costs does not include net cash proceeds of $15.0 million from the sale of the Company’s Braintree corporate headquarters in the second quarter of fiscal 2020.
FY’21 and YTD Q3 FY’22 results were impacted by the pandemic and recovery is underway

<table>
<thead>
<tr>
<th>GAAP</th>
<th>FY’21</th>
<th>YoY Change %</th>
<th>YTD Q3 FY’22</th>
<th>YoY Change %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$870</td>
<td>-12%</td>
<td>$728</td>
<td>13%</td>
</tr>
<tr>
<td>Operating Income (OI)</td>
<td>$90</td>
<td>-13%</td>
<td>$62</td>
<td>-45%</td>
</tr>
<tr>
<td>OI Margin %</td>
<td>10.3%</td>
<td>8.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$1.55</td>
<td>5%</td>
<td>$0.65</td>
<td>-63%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjusted¹</th>
<th>FY’21</th>
<th>YoY Change %</th>
<th>YTD Q3 FY’22</th>
<th>YoY Change %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$870</td>
<td>-12%</td>
<td>$728</td>
<td>13%</td>
</tr>
<tr>
<td>Operating Income (OI)</td>
<td>$155</td>
<td>-29%</td>
<td>$141</td>
<td>13%</td>
</tr>
<tr>
<td>OI Margin %</td>
<td>17.8%</td>
<td>19.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$2.35</td>
<td>-29%</td>
<td>$1.93</td>
<td>2%</td>
</tr>
</tbody>
</table>

1. For more information, including a reconciliation of GAAP to non-GAAP adjusted results, please refer to the Company’s earnings releases for the applicable periods at [http://haemonetics.gcs-web.com/](http://haemonetics.gcs-web.com/).